ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト：[email protected]AIアクセス：llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
戻る
化工社化工社 化学情報印刷レポート · 研究参考用
HCID 2441作成日：2026年10月27日

ブロマゼパム

7-ブロモ-1,3-ジヒドロ-5-(2-ピリジル)-2H-1,4-ベンゾジアゼピン-2-オン · レクトパム · 5-(2-ピリジル)-7-ブロモ-1H-1,4-ベンゾジアゼピン-2(3H)-オン · レキソミル · セニラン · 7-ブロモ-5-(2-ピリジル)-1H-1,4-ベンゾジアゼピン-2(3H)-オン · ブロマゼパム · レキソタン

https://huagongshe.com/ja/chemical/2441

ブロマゼパム の分子構造式

識別子と物理属性

CAS No.1812-30-2
分子式C14H10BrN3O
平均分子量316.15 g/mol
単同位体質量315.00072 g/mol
SMILESO=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1
InChIKeyVMIYHDSEFNYJSL-UHFFFAOYSA-N
PubChem CID2441
ChEMBLCHEMBL277062
ChEBICHEBI:31302
EC No.217-322-4
DTXSIDDTXSID40171081
現地名ブロマゼパム

化学・物理的性質

XLogP1.7
極性表面積54.4
水素結合供与体数1
水素結合受容体数3
回転可能結合数1
重原子数19
形式電荷0
複雑度385
LogP（分配係数）2.05
溶解度3.99e-02 g/L水にほとんど溶けず、エタノール (96%) および塩化メチレンに溶けにくい。
Physical DescriptionSolid
Kovats Retention Index259126262601261326332637.7
Collision Cross Section159.8 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]
融点237-238.5oC (dec.)
沸点490.7±45.0 °C(Predicted)
密度1.5573 (rough estimate)
屈折率1.6520 (estimate)
引火点11 °C
貯蔵条件2-8°C
pKa（酸解離定数）pKa 2.5(spectro, polarographic) (Uncertain)5.2(spectro, polarographic) (Uncertain)11.8(spectro, polarographic) (Uncertain)
外観・状態A crystalline solid
CAS データベース1812-30-2(CAS DataBase Reference)
NISTの化学物質情報Bromazepam(1812-30-2)

化学的特性

Crystalline Solid

安全性と法規制

GHS 分類WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]H315 (87.8%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (87.8%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (87.8%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 49 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
規制情報DEA schedule IV controlled substance2H-1,4-Benzodiazepin-2-one, 7-bromo-1,3-dihydro-5-(2-pyridinyl)-: Does not have an individual approval but may be used under an appropriate group standard
その他の安全情報IMAP assessments - 2H-1,4-Benzodiazepin-2-one, 7-bromo-1,3-dihydro-5-(2-pyridinyl)-: Environment tier I assessmentIMAP assessments - 2H-1,4-Benzodiazepin-2-one, 7-bromo-1,3-dihydro-5-(2-pyridinyl)-: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)Skin Irrit. 2 (87.8%)Eye Irrit. 2 (87.8%)STOT SE 3 (87.8%)
TreatmentGeneral supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended.

用途

用途

生化学用試薬、神経作用物質。

用途

ベンゾジアゼピン系化合物で す。GABA受容体に作用し、中枢神経抑制作 用を示します。作用時間は、中時間型とされ ています。

用途

ベンゾジアゼピン系化合物で す。GABA 受容体に作用し、中枢神経抑制作 用を示します。作用時間は、中時間型とされ ています。

説明

Bromazepam is a psychoactive benzodiazepine derivative and prescription drug that is commonly abused and often used in ‘drug-facilitated crimes’. This product is intended for forensic and research applications.

使用

Controlled substance (depressant). Anxiolytic.

健康影響They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive.
暴露経路Bioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Bromazepam is generally well absorbed after oral administration.
毒性の概要Bromazepam binds to the GABA receptor GABA<sub>A</sub>, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver InjuryDrug-Induced Liver Injury Severity and Toxicity (DILIst)BromazepamDILI PositiveDOI:10.1016/j.drudis.2019.09.022
Effects During Pregnancy and Lactation◉ Summary of Use during LactationBromazepam is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Three partially breastfed infants were apparently not adversely affected by bromazepam in milk. However, the death of a newborn infant breastfed by a mother who was apparently using bromazepam was reported. If a mother of an older infant requires bromazepam, it is not a reason to discontinue breastfeedinghowever, because of its relatively long half-life, an alternate drug is preferred, especially when nursing a newborn, preterm or sick infant.◉ Effects in Breastfed InfantsA 4-week-old infant with a 5-day history of near-miss sudden infant death syndrome was brought to the emergency room with asystole and unresponsive pupils. Despite resuscitation, the infant died. The infant’s serum contained a plasma concentration of 0.38 mcg/mL of “diazepam equivalents” and the infant’s urine was positive for bromazepam. The mother appeared to have been taking sedatives over the last few days, while partially breastfeeding, because of nervousness and sleeplessness. Bromazepam probably contributed to the infant’s death.Three infants whose mothers were taking bromazepam during pregnancy and postpartum in dosages of 1 or 2 mg three times daily were partially breastfed. No abnormalities were found at the 1-month and the 3-month checkups of any of the infants.◉ Effects on Lactation and BreastmilkRelevant published information was not found as of the revision date.
水環境危害等級（WGK）3
RTECS 番号DE9800000
輸送番号（UN）3249
毒性LD50 orally in rats: 3050 ±405 mg/kg (Goldenthal)
税関コード2933330000
危険文句（R）22-36/37/38-39/23/24/25-23/24/25-11
危険表示Xn,T,F
安全措置（S）26-36-45-36/37-16-7
危険等級6.1(b)
包装等級III